December 26, 2023

To all stakeholders,

Perseus Proteomics Inc.
Securities Code: 4882 Growth TSE
ir@ppmx.com

PPMX-T003: Announcement on Patent Registration in Japan

Perseus Proteomics Inc. (The Company) is pleased to announce that the Company has received a notification from its agent on a patent registration in Japan regarding PPMX-T003, an anti-transferrin receptor 1 antibody.

Title of invention:	AGENT FOR INHIBITING IRON UPTAKE INTO CELLS
Patent No.:	JPB7410051
Registration date:	December 25, 2023

PPMX-T003 is a blocking antibody that inhibits iron intake into cells. Its clinical trials are ongoing against polycythemia vera and aggressive NK-cell leukemia. While substance patents of this antibody have already been registered, this patent provides the pharmacological actions of this antibody as one of the basic patents. This patent registration will strengthen intellectual property rights for a broad range of therapeutic applications of PPMX-T003. The Company has also filed applications for patents in major countries.

There is no impact on the financial results for the fiscal year ending March 2024, however, the Company will strive for acquisition of rights of its important intellectual property proactively.

END